Drug intelligence / Profile preview

Sanquinnovate upstream coagulation factor modulator

Development stage: Preclinical
Lead developer: Alveron Pharma
Modality: Small Molecules

Overview

Sanquinnovate is developing a small molecule modulator of an undisclosed upstream coagulation factor for the treatment of thrombosis and bleeding disorders. Currently in the preclinical stage, this program focuses on the modulation of the coagulation cascade at an early stage to provide either antithrombotic or pro-hemostatic effects. By targeting an upstream factor, the therapy aims to achieve a more balanced modulation of hemostasis compared to downstream inhibitors. The specific molecular target remains undisclosed by the developer, but the approach is intended to offer a novel therapeutic window for managing hemostatic imbalances.

Other names: Antithrombotic/prohaemostatic therapy targets

Beyond the preview

Go deeper on Sanquinnovate upstream coagulation factor modulator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanquinnovate upstream coagulation factor modulator.

Explore the full profile